Looking to lose a few pounds? Don’t want to diet or exercise? You’re not alone: fully one-third of Americans are obese, and many companies are trying to discover the first blockbuster diet drug and make a dent in the obesity epidemic.
We’ll hear from one of those companies next month at the 12th Annual BIO Investor Forum, taking place October 8-9th in San Francisco. Cambridge-based Zafgen is hoping to bring to market their first-in-class obesity therapy, Beloranib. Unlike many other weight loss drugs, Beloranib is designed to regulate fat storage and metabolism directly, rather than by suppressing the appetite. Best of all, the drug safety profile appears to be better than current treatments, as detailed in a recent Reuters article.
Zafgen is just one of the 110 companies currently scheduled to present at the BIO Investor Forum this year; be sure to check out the full list.
Attendees at the BIO Investor Forum will also be able to hear from Syndax Pharmaceuticals, which announced today that they’ve snagged the coveted ‘breakthrough’ designation from the FDA for their breast cancer treatment entinostat, which is set to begin Phase III testing early next year. The breakthrough designation offers a faster FDA review, potentially shortening the time required to reach eventual drug approval. According to FierceBiotech, the FDA issued the designation after reviewing overall and progression-free survival data from the Phase II trials.
Also presenting at the BIO Investor Forum will be viDA Therapeutics, which is developing a potential new treatment for chronic non-healing wounds. As viDA co-founder Dr. David Granville recently told the Vancouver Sun, the discovery could have a “huge impact” for the nearly one-quarter of patients in long-term care facilities who are affected by chronic non-healing wounds. viDA’s potential treatment works by inhibiting the action of the Granzyme B, an enzyme which breaks down key proteins in the wound closure process.
These three companies are just a handful of the exciting companies we’ll hear from next month. Unfortunately, I don’t have the space here to tell you about the full lineup, but I hope you’ll be able to join us next month and learn more from the senior executives of these exciting emerging companies.